RYZB
NASDAQRayzeBio Inc.
IPO2023
Latest news
25 items- PRAxonis Therapeutics Announces $115 Million Series A Financing-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
- PRvenBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo
- NEWSAstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer TreatmentsTuesday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash plus a non-transferable contingent value right (CVR) of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. The upfront cash portion of the consideration represents a transaction value of approximately $2 billion, a 97% premium to Fusion’s closing market price of $10.64 on March 18, 2024. Related Content: Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Says AstraZeneca Is Favorably Positioned. Combined, the upfront and maximum potential contingent value payments represent, if achie
- SECSEC Form 15-12G filed by RayzeBio Inc.15-12G - RayzeBio, Inc. (0001825367) (Filer)
- INSIDERViking Global Investors Lp disposed of 6,642,700 shares (SEC Form 4)4 - RayzeBio, Inc. (0001825367) (Issuer)
- INSIDERViking Global Investors Lp disposed of 6,642,700 shares (SEC Form 4)4 - RayzeBio, Inc. (0001825367) (Issuer)
- 13D/GSEC Form SC 13G/A filed by RayzeBio Inc. (Amendment)SC 13G/A - RayzeBio, Inc. (0001825367) (Subject)
- INSIDERSEC Form 4 filed by Oliger Christy J.4 - RayzeBio, Inc. (0001825367) (Issuer)
- INSIDERSEC Form 4 filed by You Angie4 - RayzeBio, Inc. (0001825367) (Issuer)
- INSIDERSEC Form 4 filed by Van Hauwermeiren Timothy4 - RayzeBio, Inc. (0001825367) (Issuer)
- INSIDERSEC Form 4 filed by Tagliaferri Mary4 - RayzeBio, Inc. (0001825367) (Issuer)
- INSIDERHeyman Richard A. returned $22,965,375 worth of shares to the company (367,446 units at $62.50), closing all direct ownership in the company (SEC Form 4)4 - RayzeBio, Inc. (0001825367) (Issuer)
- INSIDERSEC Form 4 filed by Larson Yi4 - RayzeBio, Inc. (0001825367) (Issuer)
- INSIDERKatabi Maha returned $151,220,500 worth of shares to the company (2,419,528 units at $62.50) (SEC Form 4)4 - RayzeBio, Inc. (0001825367) (Issuer)
- INSIDERKush Arvind returned $4,902,062 worth of shares to the company (78,433 units at $62.50), closing all direct ownership in the company (SEC Form 4)4 - RayzeBio, Inc. (0001825367) (Issuer)
- INSIDERSong Kenneth returned $101,435,500 worth of shares to the company (1,622,968 units at $62.50) (SEC Form 4)4 - RayzeBio, Inc. (0001825367) (Issuer)
- SECSEC Form S-8 POS filed by RayzeBio Inc.S-8 POS - RayzeBio, Inc. (0001825367) (Filer)
- SECRayzeBio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits8-K - RayzeBio, Inc. (0001825367) (Filer)
- SECSEC Form 25-NSE filed by RayzeBio Inc.25-NSE - RayzeBio, Inc. (0001825367) (Subject)
- PRBristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical PlatformAdds RYZ101, an IND Engine and Manufacturing Capability, to BMS Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ:RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. "We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. "By strengthening and further diversifying our oncology pipeline bey
- SECSEC Form SC 14D9/A filed by RayzeBio Inc. (Amendment)SC 14D9/A - RayzeBio, Inc. (0001825367) (Subject)
- SECSEC Form SC TO-T/A filed by RayzeBio Inc. (Amendment)SC TO-T/A - RayzeBio, Inc. (0001825367) (Subject)
- PRBristol Myers Squibb Announces Expiration of RayzeBio Tender OfferBristol Myers Squibb (NYSE:BMY) today announced that its previously announced tender offer (the "Offer") to acquire all of the outstanding shares of RayzeBio, Inc. (NASDAQ:RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the "Expiration Time"). Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiration Time, approximately 53,052,499 shares of RazyeBio common stock were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 86% of the issued and outstanding shares of RayzeBio common stock at th
- NEWSBristol Myers Squibb And Rayzebio Announced Expiration Of Waiting Period Under Hart-scott-rodino Antitrust Improvements Act Of 1976, In Connection With Bristol Myers Squibb's Previously Announced Deal To Acquire Rayzebio For $62.50/Shares On Feb 9
- PRBristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting PeriodBristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb's previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. The expiration of the waiting period occurred at 11:59 p.m. EST on February 9, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240211117969/en/ Expiration of the waiting period under the HSR Act satisfies one of th
RYZB FAQ
4 questionsWhere does RYZB stock trade?
RayzeBio Inc. (RYZB) is listed on NASDAQ.When did RayzeBio Inc. go public?
RayzeBio Inc. (RYZB) completed its IPO in 2023.What are analysts saying about RYZB?
RayzeBio Inc. has had 5 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform on 2023-10-11. Recent price targets range from $2900.00 to $3500.00.How can I track RYZB on Quantisnow?
Quantisnow aggregates RayzeBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RYZB to receive live email and push alerts on every new disclosure.